TamoRx

Norway
Sandnes, Rogaland, Norway, 1010

Company profile

TamoRx company profile

TamoRx’s founding inventors have discovered a novel biological mechanism within cells that restricts the immune system from fighting cancer. The research team is focused on developing a new therapy that frees patients’ immune systems from this restriction to increase immune attack on cancer cells within tumours offering a new hope for a broad range of cancer patients. TamoRx aims to develop small molecule inhibitors that work both as a single agent and in combination with other treatments, increasing the applicability of immunotherapy for patients.

Business identity

Operating status
Active
Company type
For Profit
Founded
2016-01-01, Year

Headquarters

Postal code
1010
Country code
NO
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
1
Total equity funding
$9.9M
Last funding
Series Unknown / $9.9M / 2022-06-06
Last equity funding
Series Unknown / $9.9M
Investors
2
Lead investors
1

Founders and investors

Lead investors

Brandon Capital

Investors

Brandon CapitalUniversity of Auckland Inventors Fund